Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty

Department of Internal Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073.

OBJECTIVES. This study was designed to prospectively evaluate the routine use of continuous heparin therapy after successful uncomplicated coronary angioplasty. BACKGROUND. The use of such therapy varies among institutions and may increase the incidence of complications. Evaluation of the risks and benefits of abbreviated heparin therapy combined with early sheath removal after coronary angioplasty is necessary to determine optimal postprocedure care. METHODS. We prospectively studied 284 patients who were scheduled for elective coronary angioplasty. Historical, clinical, physiologic and angiographic data were gathered. All patients received an initial bolus of heparin and then were randomized during the procedure to receive either no additional heparin therapy or an adjusted 24-h infusion. On the basis of specific criteria, additional heparin was not withheld if procedural results suggested an increased risk for complications. RESULTS. Two hundred thirty-eight patients completed the study; 46 others were excluded in the catheterization laboratory because of unfavorable procedural results. The patients with abbreviated (n = 118) and 24-h (n = 120) therapy did not differ with respect to demographic and angiographic findings. However, the former had fewer bleeding complications (0% vs. 7%, p < 0.001) and were discharged earlier (mean +/- SD 23 +/- 11 h vs. 42 +/- 24 h, p < 0.001). One patient in this group had a major complication shortly after angioplasty. The mean savings in hospital charges in the abbreviated therapy group was $1,370 ($6,093 +/- $1,772 vs. $7,463 +/- $1,782, p < 0.001). CONCLUSIONS. Omission of routine heparin therapy after successful coronary angioplasty reduces bleeding complications without increasing patient risk. Earlier discharge and significant cost savings are possible under proper conditions.

This article has been cited by other articles:

				R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]

				K. M Jacobson, K. Hall Long, E. K McMurtry, J. M Naessens, and C. S Rihal The economic burden of complications during percutaneous coronary intervention Qual. Saf. Health Care, April 1, 2007; 16(2): 154 - 159. [Abstract] [Full Text] [PDF]

				P. M. Meyers, C. C. Phatouros, and R. T. Higashida Hyperperfusion Syndrome After Intracranial Angioplasty and Stent Placement Stroke, September 1, 2006; 37(9): 2210 - 2211. [Full Text] [PDF]

				J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]

				G. N. Levine, M. J. Kern, P. B. Berger, D. L. Brown, L. W. Klein, D. J. Kereiakes, T. A. Sanborn, A. K. Jacobs, and for the American Heart Association Diagnostic and Management of Patients Undergoing Percutaneous Coronary Revascularization Ann Intern Med, July 15, 2003; 139(2): 123 - 136. [Abstract] [Full Text] [PDF]

				S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]

				J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119(1_suppl): 321S - 336S. [Full Text] [PDF]

				M. Rabah, D. Mason, D. W. M. Muller, R. Hundley, A. D. Kugelmass, B. Weiner, L. Cannon, W. W. O'Neill, and R. D. Safian Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention J. Am. Coll. Cardiol., August 1, 1999; 34(2): 461 - 467. [Abstract] [Full Text] [PDF]

				S. H. Duda, J. Wiskirchen, M. Erb, U. Schott, K. Khaligi, P. L. Pereira, J. Albes, and C. D. Claussen Suture-mediated Percutaneous Closure of Antegrade Femoral Arterial Access Sites in Patients Who Have Full Anticoagulation Therapy Radiology, January 1, 1999; 210(1): 47 - 52. [Abstract] [Full Text]

				A GARACHEMANI and B MEIER Heparin for coronary angioplasty: high dose, low dose, or no dose? Heart, July 1, 1998; 80(1): 3 - 4. [Full Text]

				A. D. Kugelmass and G. E. Raskob Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S24 - S31. [PDF]

				The EPILOG Investigators Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization N. Engl. J. Med., June 12, 1997; 336(24): 1689 - 1697. [Abstract] [Full Text] [PDF]

				Abbreviated Heparin after PTCA Cuts Costs and Complications Journal Watch Cardiology, January 1, 1995; 1995(101): 19 - 19. [Full Text]

				ABBREVIATED HEPARIN REDUCES COMPLICATIONS AND COSTS AFTER PTCA Journal Watch (General), November 15, 1994; 1994(1115): 4 - 4. [Full Text]